BGMSP Key Statistics, Chart & Performance
The current stock price of BGMSP is 3.76 USD. In the past month the price decreased by -9.4%.
BGMSP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B |
Related stock screener links
About BGMSP
Company Profile
Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
Company Info
BIO GREEN MED SOLUTION - BGMS 6 PERP
Level 10, Tower 11, Avenue 5, No. 8, Jalan Kerinchi
KUALA LUMPUR NEW JERSEY MY
Employees: 0
Phone: 609085177330
BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ
What does BGMSP do?
Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
Can you provide the latest stock price for BIO GREEN MED SOLUTION - BGMS 6 PERP?
The current stock price of BGMSP is 3.76 USD. The price increased by 1.62% in the last trading session.
Does BGMSP stock pay dividends?
BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a dividend yield of 12.16%. The yearly dividend amount is currently 0.
What is the ChartMill rating of BIO GREEN MED SOLUTION - BGMS 6 PERP stock?
BGMSP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the upcoming dividend date for BIO GREEN MED SOLUTION - BGMS 6 PERP?
The next ex-dividend date for BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is October 20, 2025.
What is the outstanding short interest for BIO GREEN MED SOLUTION - BGMS 6 PERP?
The outstanding short interest for BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is 0.02% of its float.
BGMSP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BGMSP.
BGMSP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BGMSP. The financial health of BGMSP is average, but there are quite some concerns on its profitability.
BGMSP Financial Highlights
Over the last trailing twelve months BGMSP reported a non-GAAP Earnings per Share(EPS) of -80.13. The EPS increased by 96.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.49% | ||
| ROE | -98.28% | ||
| Debt/Equity | 0 |
BGMSP Forecast & Estimates
For the next year, analysts expect an EPS growth of 39.49% and a revenue growth 88.68% for BGMSP